Carlos Alvarez Mendoza

He completed his BSc HONS in Medical Biochemistry at Kingston University before going on to study an MSc in Cancer at University College London. He has worked at the UCL Cancer Institute, Wolfson Institute of Population Health, and Queensland Brain Institute where his past research areas included DNA damage pathways in Osteosarcoma, HPV methylation in cervical cancer and early response genes in neurodevelopment.

 

BSc Hons Medical Biochemistry – Kingston University

MSc Cancer – University College London

 

Zoumpoulidou, G., Alvarez-Mendoza, C., Mancusi, C. et al. Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma. Nat Commun 12, 7064 (2021). https://doi.org/10.1038/s41467-021-27291-8

 

Goncalves T, Zoumpoulidou G, Alvarez-Mendoza C, Mancusi C, Collopy LC, Strauss SJ, Mittnacht S, Tomita K. Selective Elimination of Osteosarcoma Cell Lines with Short Telomeres by Ataxia Telangiectasia and Rad3-Related Inhibitors. ACS Pharmacol Transl Sci. 2020 Oct 7;3(6):1253-1264. doi: 10.1021/acsptsci.0c00125. PMID: 33344901; PMCID: PMC7737214.

 

Hurt CN, Nedjai B, Alvarez-Mendoza C, Powell N, Tristram A, Jones S. Combined HPV 16 E2 and L1 methylation predict response to treatment with cidofovir and imiquimod in patients with vulval intraepithelial neoplasia. Cancer Biomark. 2022;35(2):143-153. doi: 10.3233/CBM-210448. PMID: 35912731; PMCID: PMC9661315.